OPKO HEALTH INC
For the period ended Dec 31, 2024. Filed Mar 3, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 3, 2025
OPK$1.710.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
(In thousands)
| For the years ended December 31, | |||
|---|---|---|---|
| 2024 | 2023 | 2022 | |
| Cash flows from operating activities: | |||
| Net loss | $(53,224) | $(188,863) | $(328,405) |
| Adjustments to reconcile net loss to net cash provided by (used in) operating activities: | |||
| Depreciation and amortization | 98,176 | 105,297 | 108,655 |
| Non-cash interest | 17,547 | 2,750 | 2,750 |
| Amortization of deferred financing costs | 1,974 | 1,222 | 1,161 |
| Losses from investments in investees | 18 | 107 | 383 |
| Equity-based compensation – employees and non-employees | 11,048 | 11,413 | 18,509 |
| Realized loss (gain) on disposal of fixed assets and sales of equity securities | (63,397) | 1,321 | (455) |
| Change in fair value of equity securities and derivative instruments | (114,429) | 17,647 | 153,835 |
| Loss on conversion convertible senior notes | (6,628) | — | — |
| Change in fair value of contingent consideration | — | (1,036) | (1,312) |
| Deferred income tax provision | 14,744 | 146 | (74,405) |
| Gain on sale of assets | (121,493) | — | (18,559) |
| Changes in assets and liabilities, net of the effects of acquisitions: | |||
| Accounts receivable, net | (220) | 3,411 | 128,602 |
| Inventory, net | 4,217 | 15,197 | 13,662 |
| Other current assets and prepaid expenses | (3,979) | 7,164 | (3,416) |
| Other assets | 237 | (288) | 1,935 |
| Accounts payable | (20,662) | 2,828 | (9,388) |
| Foreign currency measurement | 3,899 | (1,036) | 2,369 |
| Accrued expenses and other liabilities | 48,683 | (5,477) | (91,110) |
| Net cash used in operating activities | (183,489) | (28,197) | (95,189) |
| Cash flows from investing activities: | |||
| Investments in investees | — | (5,000) | — |
| Proceeds from sale of investments | 166,604 | 364 | 115,423 |
| Acquisition of businesses, net of cash acquired | — | — | (1,758) |
| Proceeds from the sale of property, plant and equipment | 242 | 2,713 | 1,951 |
| Capital expenditures | (25,010) | (16,275) | (24,578) |
| Proceeds from LabCorp Sale | 210,378 | — | — |
| Net cash provided by (used in) investing activities | 352,214 | (18,198) | 91,038 |
| Cash flows from financing activities: | |||
| Issuance of 3.00% convertible senior notes, net (including related parties) | 230,000 | — | — |
| Issuance of 2044 Notes | 250,000 | — | — |
| Debt issuance costs | (13,385) | — | — |
| Share repurchase | (90,223) | — | — |
| Net activity from the exercise of common stock options and warrants | (208) | (272) | (774) |
| Repurchase of 2029 Convertible Notes | (30,102) | — | — |
| Borrowings on lines of credit | 459,432 | 671,678 | 1,059,519 |
| Repayments of lines of credit | (475,061) | (679,709) | (1,035,774) |
| Redemption of 2025 Notes and 2033 Senior Notes | (146,287) | (3,000) | — |
| Net cash provided by (used in) financing activities | 184,166 | (11,303) | 22,971 |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | (3,157) | 388 | (339) |
| Net decrease in cash, cash equivalents and restricted cash | 349,734 | (57,310) | 18,481 |
| Cash, cash equivalents and restricted cash at beginning of period | 95,881 | 153,191 | 134,710 |
| Cash, cash equivalents and restricted cash at end of period | $445,615 | $95,881 | $153,191 |
| SUPPLEMENTAL INFORMATION: | |||
| Interest paid | $20,883 | $8,135 | $7,420 |
| Income taxes paid, net of refunds | $10,008 | $3,712 | $8,037 |
| Operating lease right-of-use assets obtained in exchange for lease obligations | $— | $29,363 | $— |
| Assets acquired by finance leases | $— | $203 | $4,717 |
| Non-cash financing: | |||
| Shares issued upon the conversion of: | |||
| Common Stock options and warrants, surrendered in net exercise | $529 | $301 | $1,268 |
| Issuance of common stock for acquisition of ModeX | $— | $— | $221,662 |
| Fair value of shares included in consideration from GeneDx Holdings | $— | $6,689 | $172,000 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.